Fig. 6

Responsiveness of risk score to PD-L1 blockade immunotherapy in the IMvigor210 cohort. A Prognostic differences between risk score groups in the IMvigor210 cohort. B Risk score differences in immunotherapy responses in the IMvigor210 cohort; C distribution of immunotherapy responses between risk score groups in the IMvigor210 cohort; D prognostic differences between risk score groups in early-stage patients in the IMvigor210 cohort; E prognostic differences between risk score groups in advanced-stage patients in the IMvigor210 cohort; F prognostic differences in risk score groups in the GSE78220 cohort; G risk score differences in immunotherapy responses in the GSE78220 cohort; H distribution of immunotherapy responses between risk score groups in the GSE78220 cohort. *P < 0.05; **P < 0.01